(919) 237-4897 info@t3dtherapeutics.com

T3D Therapeutics, Inc. today announced that final Phase 2a data with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in a session at the 2018 Alzheimer’s Association International Conference (AAIC) entitled ‘Novel Therapeutic Approaches for Neurodegenerative Disease’. The oral presentation was entitled ‘Effects of a PPAR Delta/Gamma Agonist, T3D-959, on Metabolic and Cognitive Functions in Mild to Moderate Alzheimer’s Disease Subjects’. <See 2018 AAIC Presentation>